Jan Eckmann

Penzberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies.

Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies.

Journal: Journal for immunotherapy of cancer
Published: March 27, 2026

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Journal: Nature medicine
Published: June 23, 2025

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.

Journal: Molecular cancer therapeutics
Published: May 21, 2025

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice.

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice.

Journal: mAbs
Published: December 17, 2024

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Journal: Blood
Published: July 10, 2024

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.

Journal: Frontiers in immunology
Published: April 02, 2024

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Journal: Blood
Published: November 27, 2023

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

Journal: Leukemia
Published: October 21, 2023

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.

Journal: Frontiers in oncology
Published: January 23, 2023

Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.

Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.

Journal: Cancer research
Published: December 03, 2021

Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.

Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2021

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.

Journal: Nature cancer
Published: March 01, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026